Elecoglipron
Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders. It is a glucagon-like peptide-1 receptor agonist.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370309108 under CC BY-SA 4.0; modifications have been made.